Investor Presentation First Nine Months of 2023
128
Investor presentation
First nine months of 2023
Rest of World at a glance
Rest of World
Million
300
Diabetes trend in population
21%
DKK
billion
Diabetes market by value and
Novo Nordisk market share
250
18%
60
80
200
60
150
286
40
227
40
100
187
Novo Nordisk reported sales
First nine months
of 2023
MS
Sales
(MDKK)
Growth²
Injectable GLP-13
6,286
43%
100%
RybelsusⓇ
2,171
146%
Total GLP-1
8,457
61%
GLP-1 80%
Total insulin4
60
35.7%1
7,597
5%
Other Diabetes care5
330
-37%
2.2%1
Insulin
60%
Diabetes care
16,384
26%
Obesity care
1,907
37%
40%
5.4%1
20
50
20
Diabetes & Obesity
18,291
27%
OAD
20%
care
Rare disease7
2,669
-28%
0
2021
0
0%
2030
2045
Aug
2018
Aug
2023
Total
20,960
16%
Population with diabetes
Diabetes growth rate
GLP-1 MS
-Insulin MS
OAD MS
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: South & Central America, Southeast Asia
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Aug 2023: Novo Nordisk 59%,
Others 41%; Competitor GLP-1 value market shares, as of Aug 2023: Novo Nordisk
82%, Others 18%. OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT,
Aug 2023 value figures; Market values are based on the list prices
2 At constant exchange rates; ³ Comprises VictozaⓇ, Ozempic®;
4 Comprises TresibaⓇ, XultophyⓇ, Levemir®, NovoMix®, Ryzodeg®, NovoRapidⓇ
and FiaspⓇ5 Comprises Novo NormⓇ and needles; 6 Comprises SaxendaⓇ;
Comprises primarily Esperoct®, Refixia®, NovoSeven®, Novo Eight® and
NorditropinⓇView entire presentation